Results 231 to 240 of about 12,047 (282)
Antimicrobial Agents and Chemotherapy, 2021 A total of 15 Candida auris isolates from the SENTRY antimicrobial surveillance program between 2006 and 2019 were combined with 21 isolates from other collections for the evaluation of antifungal susceptibility and synergy against anidulafungin plus ...
Lalitagauri M Deshpande +2 more
exaly +2 more sources
Journal of Antimicrobial Chemotherapy, 2020 BACKGROUND Epidemiological cut-off values and clinical interpretive breakpoints have been developed for a number of antifungal agents with the most common Candida species that account for the majority of infections due to pathogenic yeasts species ...
Andrew M Borman +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2004
Anidulafungin is a novel antifungal agent which, like other echinocandins, inhibits beta-(1,3)-D-glucan synthase and disrupts fungal cell-wall synthesis. It has marked antifungal activity against a broad spectrum of Candida spp. and Aspergillus spp., including amphotericin B- and triazole-resistant strains.
David, Murdoch, Greg L, Plosker
+5 more sources
Anidulafungin is a novel antifungal agent which, like other echinocandins, inhibits beta-(1,3)-D-glucan synthase and disrupts fungal cell-wall synthesis. It has marked antifungal activity against a broad spectrum of Candida spp. and Aspergillus spp., including amphotericin B- and triazole-resistant strains.
David, Murdoch, Greg L, Plosker
+5 more sources
Infectious Diseases in Clinical Practice, 2005
Anidulafungin (LY-303366, VER002) is a semisynthetic derivative of echinocandin B and a potent antifungal agent active against a wide spectrum of fungal pathogens. We reviewed published papers, abstracts, and data to provide an overview focusing on the microbiology of anidulafungin and its promise for treating fungal infections. Anidulafungin was found
Mahmoud Ghannoum, Maurissa D'Angelo
openaire +1 more source
Anidulafungin (LY-303366, VER002) is a semisynthetic derivative of echinocandin B and a potent antifungal agent active against a wide spectrum of fungal pathogens. We reviewed published papers, abstracts, and data to provide an overview focusing on the microbiology of anidulafungin and its promise for treating fungal infections. Anidulafungin was found
Mahmoud Ghannoum, Maurissa D'Angelo
openaire +1 more source
Hospital Pharmacy, 2006
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
Journal of Antimicrobial Chemotherapy, 2019
BACKGROUND Candida auris is an emerging MDR pathogen. It shows reduced susceptibility to azole drugs and, in some strains, high amphotericin B MICs have been described. For these reasons, echinocandins were proposed as first-line treatment for C.
Guillermo Garcia-Effron
exaly +2 more sources
BACKGROUND Candida auris is an emerging MDR pathogen. It shows reduced susceptibility to azole drugs and, in some strains, high amphotericin B MICs have been described. For these reasons, echinocandins were proposed as first-line treatment for C.
Guillermo Garcia-Effron
exaly +2 more sources
The Pediatric Infectious Disease Journal, 2019
Background: Treatment with an echinocandin is recommended as first-line therapy for patients with invasive candidiasis (ICC) including candidemia. Little is known about the efficacy and safety of anidulafungin in children with ICC.
E. Roilides +8 more
semanticscholar +1 more source
Background: Treatment with an echinocandin is recommended as first-line therapy for patients with invasive candidiasis (ICC) including candidemia. Little is known about the efficacy and safety of anidulafungin in children with ICC.
E. Roilides +8 more
semanticscholar +1 more source